Navigation Links
Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
Date:5/22/2008

CAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The fourth clinical stage antibody is MT293 which is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on ou
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
2. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
3. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
6. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
7. Micromet Announces Changes in Management Team
8. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
9. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
10. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
11. Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 In conjunction with DURECT Corporation,s ... results press release, you are invited to listen to ... the internet on Thursday, August 7, 2014 at 4:30 ... A live audio webcast of the presentation will be ... and clicking "Investor Relations."  If you are unable to ...
(Date:7/30/2014)... , July 30, 2014 PuraMed BioScience ... marketer of over-the-counter (OTC) medicinal and healthcare products, ... M name along with the name,s red ... with the trademarked name MigraPure ®  going ... of PuraMed,s homeopathic, natural migraine pain reliever will ...
(Date:7/30/2014)... /PRNewswire-iReach/ -- Transluminal Technologies LLC, a ... announced today that they have received CE Mark ... Velox CD™ provides a safe and predictable means ... The single size velox CD™ is indicated for ... to 8F.  Velox CD™ utilizes patented ...
Breaking Medicine Technology:DURECT Corporation Invites You to Join its Second Quarter 2014 Earnings Conference Call 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 3Transluminal Technologies receives CE Mark approval for velox CD(TM) vascular closure device 2
(Date:7/30/2014)... July 31, 2014 “United States Orthopedic Braces ... on the United States Orthopedic Braces and Supports market. The ... (in units) and average price data (in US dollars), within ... , Ankle Braces and Supports , ... and Supports. , Orthotics is a specialty within ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Nationally recognized ... CNE, ANEF, who since September 2013 has served as ... became the new dean of the College of Nursing ... move marries her leadership of the NLN, as the ... the top-ranked academic nursing and research institutions in the ...
(Date:7/30/2014)... 2014 New changes are in store for ... move to a new facility. The official date of the ... moving soon. , MedX Pharmacy will be moving into a ... 77581. This is the old Wells Fargo building. The new ... include a drive thru for convenient drop-off and pick-up of ...
(Date:7/30/2014)... Serial entrepreneur, Paul Mata, spent the early part ... most people, in 2008 he suffered extreme financial hardship and ... Paul carefully studied the difference between people who have sustainable ... on the knowledge he acquired, he was able to use ... health, but also grow his clients' personal and financial assets ...
(Date:7/30/2014)... revitalized and expanded through a U.S.-funded effort that ... access and providing cutting-edge skills labs and other ... by participants of the $130 million Medical Education ... progress being made at the African institutions. Their ... by the journal Academic Medicine . Begun ...
Breaking Medicine News(10 mins):Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 2Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 3Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 4Health News:National League for Nursing Congratulates League President Marsha Adams on Appointment as Dean of College of Nursing at University of Alabama-Huntsville 2Health News:National League for Nursing Congratulates League President Marsha Adams on Appointment as Dean of College of Nursing at University of Alabama-Huntsville 3Health News:MedX Pharmacy Relocates to New Facility 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 3Health News:Journal supplement details progress in African medical education 2Health News:Journal supplement details progress in African medical education 3
... at 6th International Stem Cell Symposium Seoul, Korea - ... ... AlphaMed Press,publisher of the peer-reviewed journal STEM CELLS(R), announces that the,annual ... will be presented on June 20, 2008 in,Seoul, Korea. The US$10,000 award ...
... need, but sickest still going without, study finds , , TUESDAY, ... has resulted in some improvements for seniors but no real ... finds that Medicare beneficiaries are less likely to forego basic ... sickest patients are still skipping meds due to burdensome costs. ...
... winners from Indiana, South Carolina and Illinois are Runners-Up, ... a business niche when a friend had trouble finding ... the Year for turning his,idea into a multi-million dollar ... at the U.S. Small Business,Administration,s celebration of National Small ...
... for Policymakers, Consumers and the Media is First ... and Consumer Product,Issues, WASHINGTON, April 22 ... A Guide for,Consumers, Policymakers and the Media, the ... to provide current and scientifically accurate,information and resources ...
... greatest week after meds begin , , TUESDAY, April 22 ... are 60 percent more likely to develop pneumonia in the ... new study shows. , The risk is greatest during the ... decreases, say Dutch researchers. , "The risk of developing pneumonia ...
... Ensign,Group, Inc. (Nasdaq: ENSG ), the parent ... care services and assisted living,companies, announced today that ... results following the market close on Wednesday, May ... Conference Call, Ensign invites current and prospective ...
Cached Medicine News:Health News:Stem Cells(R) and International Stem Cell Symposium Present Annual Stem Cells(R) Young Investigator Award 2Health News:Medicare Prescription Drug Benefit Shows Mixed Results 2Health News:Medicare Prescription Drug Benefit Shows Mixed Results 3Health News:Online Job Search Company from Virginia is National Small Business of the Year 2Health News:Online Job Search Company from Virginia is National Small Business of the Year 3Health News:Online Job Search Company from Virginia is National Small Business of the Year 4Health News:Grocery Manufacturers Association Releases Science Policy Paper on Bisphenol A 2Health News:Antipsychotic Drugs Linked to Pneumonia in Elderly 2Health News:The Ensign Group Schedules 2008 First Quarter Earnings Call for Thursday, May 8, 2008 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: